OKUR
OnKure Therapeutics, Inc.·Healthcare
4.30
0.467%(+0.02)
Market ClosedLast Updated: — ET
52W L: $1.7052W H: $4.75
OKUR NEWS
globenewswire.com
Mar 27
OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies
-- Financing led by Access Biotechnology with participation from new and existing investors -- Financing to support advancement of two next-generation PI3Kα pan-mutant inhibitors for breast cancer and vascular anomalies – expect to file INDs for each program in 1H 2027 -- Liam Ratcliffe Joins OnKure's Board of Directors BOULDER, Colo., March 27, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it has entered into a securities purchase agreement for a private placement with certain institutional and accredited healthcare investors, raising gross proceeds of approximately $150 million.
globenewswire.com
Mar 12
OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
-- Data from the ongoing PIKture-01 trial is expected to be announced in March 2026 ; continued enrollment in breast cancer triplet combinations
defenseworld.net
Feb 10
OnKure Therapeutics, Inc. (NASDAQ:OKUR) Given Consensus Rating of “Hold” by Analysts
Shares of OnKure Therapeutics, Inc. (NASDAQ: OKUR - Get Free Report) have been assigned an average rating of "Hold" from the five analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the
